BioHealth & Medical Analyst Calls (AZN, NVS, NVO, CRL, IVGN, APPY, TWTI)

June 24, 2008 · Filed Under General 

BNP Paribas overseas has lowered ratings of AstraZeneca (NYSE: AZN) to Underperform from Neutral; and raised Novartis (NYSE: NVS) to Neutral from Underperform.

Goldman Sachs has raised Novo Nordisk (NYSE: NVO) to Buy from Neutral; Charles River Laboratories (NYSE: CRL) downgraded to Neutral at Goldman Sachs.

JPMorgan has raised its rating on Invitrogen (NASDAQ: IVGN) to Overweight from Neutral.

Lazard Capital Markets started coverage of Aspenbio (NASDAQ: APPY) with a “Buy” rating.

R.W.Baird Downgraded Third Wave Technologies (NASDAQ: TWTI) to Neutral from Outperform.

Jon Ogg
June 24, 2008


Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed